Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Johnathan Friedberg"'
Autor:
Fateeha Furqan, Kwang W. Ahn, Yue Chen, Manmeet Kaur, Syed A. Abutalib, Nausheen Ahmed, Sairah Ahmed, Mohamed A. Kharfan‐Dabaja, Johnathan Friedberg, Tara Gregory, LaQuisa Hill, Cole Sterling, Stephan K. Barta, Mazyar Shadman, Miguel‐Angel Perales, Jasmine Zain, Alex F. Herrera, Craig Sauter, Mehdi Hamadani
Publikováno v:
British Journal of Haematology. 200:54-63
The prognosis of relapsed/refractory (R/R) anaplastic large cell lymphoma (ALCL) is poor. Large studies evaluating outcomes of allogeneic haematopoietic cell transplantation (allo-HCT) in systemic R/R ALCL are not available. Using the Center for Inte
Autor:
Steven Grant, Simon S. Jones, Steven N. Quayle, Johnathan Friedberg, Hiral Patel, Girija Dasmahapatra
Interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib were examined in non-Hodgkin lymphoma (NHL) models, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95f06edc5f1fb7848af26fc07f34e456
https://doi.org/10.1158/1535-7163.c.6536230
https://doi.org/10.1158/1535-7163.c.6536230
Autor:
Steven Grant, Simon S. Jones, Steven N. Quayle, Johnathan Friedberg, Hiral Patel, Girija Dasmahapatra
Supplementary Figures and Tables. Fig 1: Synergistic interactions between CFZ and ACY1215 lead to induction of apoptosis in a time-dependent manner. Fig 2: Knocking down HDAC6 expression by shRNA or pharmacologic inhibition by ACY1215 or Tubastatin A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b832d2fa81fd503791c61bf850334a4
https://doi.org/10.1158/1535-7163.22499704.v1
https://doi.org/10.1158/1535-7163.22499704.v1
Autor:
Girija Dasmahapatra, Hiral Patel, Johnathan Friedberg, Steven N. Quayle, Simon S. Jones, Steven Grant
Publikováno v:
Molecular Cancer Therapeutics. 18:1181-1181
Autor:
Hiral Patel, Johnathan Friedberg, Simon S. Jones, Steven N. Quayle, Girija Dasmahapatra, Steven Grant
Publikováno v:
Molecular cancer therapeutics. 13(12)
Interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib were examined in non-Hodgkin lymphoma (NHL) models, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and